Latest Business Development News

Page 1 of 38
Actinogen Medical’s pivotal XanaMIA trial produced a mixed result: Xanamem showed a small, non-significant benefit across the full 247-patient population, but a prespecified older-patient analysis found a statistically significant difference in disease stabilisation. The company will continue its open-label extension, suspend future Phase 3 spending and seek development partners.
Victor Sage
Victor Sage
19 Nov 2026
Dotz Nano has repriced its A$2 million placement after CEO and director Nati Harpaz resigned for health reasons, increasing the proposed share issue while adding more generous attaching options. The company has also clarified that its September quarterly report described commitments as a completed raise even though no shares or funds had then changed hands.
Victor Sage
Victor Sage
18 Nov 2026
IPH has opened FY27 with an 8.4% revenue decline and a 13.4% fall in underlying EBITDA, with currency movements only partly explaining the weakness. New CEO Tony O’Malley says restoring organic growth in Australia and New Zealand is now a clear priority.
Victor Sage
Victor Sage
17 Nov 2026
Clover Corporation has entered FY27 with stronger margins, no interest-bearing debt and revenue momentum after reporting a 50% rise in FY26 NPAT. The company expects first-half FY27 revenue of about $60 million and says full-year revenue and earnings could outperform FY26 if current conditions persist.
Victor Sage
Victor Sage
17 Nov 2026
Neurizon has opened a non-underwritten A$2 million share purchase plan at A$0.068 a share, giving eligible shareholders access to the same terms as its recent placement. Participants may also receive one free option for each new share, subject to shareholder approval and ASX quotation conditions, as the company funds its NUZ-001 ALS program towards a late Q2 2027 readout.
Ada Torres
Ada Torres
16 Nov 2026
Biotron CEO and executive director Glenn Gilbert has started more than two months ahead of schedule, immediately taking charge of a strategic review centred on SedRx. The review will also test development priorities, capital allocation and partnering options across the company’s drug portfolio.
Ada Torres
Ada Torres
9 Nov 2026
SRJ Technologies has replaced both its chair and chief executive as it turns from international expansion toward operational delivery and revenue conversion. Ben Lumley will serve as interim CEO with an initial two-month review period, while Mark Lindh becomes chair.
Victor Sage
Victor Sage
4 Nov 2026
Amgen delivered 8% third-quarter revenue growth and a 19% increase in GAAP diluted EPS, while newer medicines continued to expand. The result came alongside sharp declines in Prolia and XGEVA sales from biosimilar competition and a busy pipeline of late-stage programmes.
Victor Sage
Victor Sage
4 Nov 2026
Pfizer has lifted its 2026 revenue and adjusted earnings guidance after a quarter in which newer and acquired medicines grew strongly enough to offset steep declines in COVID-19 products. Overall revenue was flat, while reported net income fell 8%.
Victor Sage
Victor Sage
4 Nov 2026
4DMedical has denied holding undisclosed information that could explain a sharp sell-off in its shares, after ASX queried a fall from $3.28 to $2.41. The company said it believes increased short interest was responsible and confirmed compliance with continuous disclosure rules.
Victor Sage
Victor Sage
2 Nov 2026
Neurizon Therapeutics has secured A$4.3 million through a discounted placement and is seeking another A$2.0 million from eligible shareholders, while redeeming its remaining Obsidian convertible notes. The move removes current note-conversion dilution, but shifts funding risk towards equity holders ahead of a pivotal NUZ-001 trial readout.
Ada Torres
Ada Torres
2 Nov 2026
Pathkey.AI has secured its first Chipforge customer contract ahead of the semiconductor platform’s commercial release, while a $2.8 million placement lifted quarter-end cash to $5.83 million. The company remains early-stage, with just $10,000 in customer receipts during the September quarter and further commercial conversion still to prove.
Sophie Babbage
Sophie Babbage
30 Oct 2026

Browse the archive

Full archive